Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold at the 2019 International Cartila...
June 05 2019 - 8:00AM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced plans to showcase HYALOFAST, a
biodegradable, HA-based scaffold for cartilage repair, along with
its regenerative medicine and orthobiologics portfolio, at the 2019
International Cartilage Regeneration and Joint Preservation Society
(ICRS) Focus Meeting. HYALOFAST will be featured in the meeting’s
scientific program in a special session on scaffolds, led by Dr.
Boguslaw Sadlik, head of the Biological Joint Reconstruction
Department at the St. Luke’s Hospital in Bielsko- Biala, Poland. In
addition, Anika will host an educational symposium on the use of
HYALOFAST for one-step cartilage repair, and highlight its
commercial portfolio, which includes CINGAL and MONOVISC, at its
booth. The 2019 ICRS Focus Meeting, entitled One-Step Cartilage
Repair, will be held in Rome at the Cicerone Hotel on June 5-7,
2019.
“We look forward to a cadre of internationally-recognized
cartilage repair specialists sharing their extensive clinical
experience with HYALOFAST and demonstrating its clinical utility
and ease of use at one of the world’s largest gatherings of
cartilage repair surgeons,” said Joseph Darling, President and CEO,
Anika Therapeutics. “True to the theme of this year’s ICRS Focus
Meeting, HYALOFAST represents a remarkable advance in supporting
cartilage regrowth using a convenient, one-step, minimally-invasive
procedure that can be tailored to each individual patient’s
needs.”
Dr. Sadlik added, “By applying HYALOFAST in combination with
Bone Marrow Stimulation Techniques or other cell therapies to treat
cartilage lesions, I have enhanced my patients’ quality of life
while achieving very satisfying and sustaining clinical results.
HYALOFAST is rather easy to use, specifically in minimal invasive
arthroscopic surgery. During the ICRS Focus Meeting in Rome I will
be sharing my clinical experience and some tips and tricks from my
experience with the product.”
HYALOFAST is a non-woven, single-step, off-the-shelf, and
cost-effective biodegradable HA-based scaffold for hyaline-like
cartilage regeneration to treat cartilage injuries and defects.
HYALOFAST is commercially available in over 15 countries and has
been used to successfully treat more than 16,000 patients
internationally, with strong ten-year patient follow-up data.
HYALOFAST is pending regulatory submission in the United States and
currently enrolling patients in its global, multicenter FastTRACK
Phase III trial.
Details on HYALOFAST presentations at the 2019 ICRS Focus
Meeting are below:
June 5, 2019Anika-sponsored Educational
Symposium12:00 – 12:45 pm Central European Standard Time (CEST)
– Cicerone Room, The Cicerone HotelTitle: “Hyalofast, the
hyaluronic acid- based scaffold for one step cartilage
repair”Speakers:
- Dr. Alberto Gobbi: OASI Bioresearch
Foundation, Milano – Italy“Hyalofast plus BMAC in Osteochondral
Lesions of the Knee: Long Term Clinical Evidence”
- Dr. Konrad Slynarski – Gamma Medical
Center, Warsaw – Poland“From Bench to Bedside - 18 Years of My
Experience with Hyalofast Scaffold”
- Dr. Gorav Datta: University Hospital,
Southampton – United Kingdom“Hyalofast Arthroscopic Implantation in
the Hip: Surgical Technique and Clinical Evidence”
June 6, 2019Special Session III – Scaffolds8:30 –
11:00 CESTSpeaker: Dr. Sadlik Boguslaw
Company-Sponsored Booth #3As one of the Platinum
sponsors, Anika’s booth will feature interactive demonstrations of
the HYALOFAST surgical procedure using its virtual simulator, and
showcase its viscosupplement portfolio, including CINGAL and
MONOVISC.
About ICRSThe ICRS (International Cartilage Regeneration
and Joint Preservation Society) is the main forum for international
collaboration in cartilaginous tissue research that brings together
basic scientists, clinical researchers, physicians and members of
industry, engaged or interested in the field of articular biology,
its genetic basis and regenerative medicine. It provides continuing
education and training to physicians and scientists with an active
interest in the prevention and treatment of joint disease to
improve patient care through regenerative medicine approaches.
About Anika Therapeutics, Inc.Anika Therapeutics,
Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and
regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190605005243/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev,
917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024